Breast Cancer, Esophageal Cancer, Lung Cancer, Miscellaneous Neoplasm
Conditions
Keywords
Cancer, Digital pet, Conventional pet
Brief summary
In this study, the investigators will analyze the impact of digital PET/CT on the final diagnostic conclusion of the scan in patients with lung cancer, breast cancer, esophageal cancer and a group of mescellaneous cancers.
Detailed description
There will be a single injection of the PET radiopharmaceutical FDG, followed by a conventional PET/CT scan and a digital PET scan, in this order or vice versa.
Interventions
DIAGNOSTIC_TESTDigital PET/CT scan
The digital PET/CT scan will be acquired before or after the conventional PET/CT scan.
Sponsors
Philips Healthcare
Isala
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Intervention model description
All included patients will have two PET scans, one on the conventional PET (Ingenuity TF, Philips Healthcare) and one on the digital PET (Vereos, Philips Healthcare). The order of the two PET scans will differ per patient.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
In order to be eligible to participate in this study, a subject must meet all of the following criteria: * referred to Isala for a clinically indicated FDG-PET/CT scan * suspected or proven lung cancer, esophageal cancer, breast cancer or miscellaneous cancer, either as a primary diagnosis or follow-up study * signed informed consent
Exclusion criteria
A potential subject who meets any of the following criteria will be excluded from participation in this study: * age \< 18 years * incapacitated adults * prisoners * pregnant patients * unable to undergo two consecutive PET/CT scans
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Diagnostic outcome of the PET/CT study | approximately 2 hours |
Secondary
| Measure | Time frame |
|---|---|
| PET image quality | approximately 2 hours |
Countries
Netherlands
Outcome results
None listed